Tanno Luciana Kase, Berard Frédéric, Beaudoin Etienne, Didier Alain, Demoly Pascal
Division of Allergy, Département de Pneumologie et Addictologie, University Hospital of Montpellier, 34295 Montpellier, France.
WHO Collaborating Center for Classification Scientific Support, University Hospital of Montpellier, 34295 Montpellier, France.
Vaccines (Basel). 2021 May 27;9(6):560. doi: 10.3390/vaccines9060560.
Vaccines against COVID-19 (and its emerging variants) are an essential global intervention to control the current pandemic situation. Anaphylactic reactions have been reported after SARS-CoV2 RNA vaccines. Anaphylaxis is defined as a severe life-threatening generalized or systemic hypersensitivity reaction. This risk is estimated at 1/1,000,000 in the context of vaccine safety surveillance programs. The COVID-19 vaccination is rolling-out vastly in different courtiers and surveillance programs are key to monitor severe adverse reactions, such as anaphylaxis. Anaphylaxis due to vaccine is extremely rare and specific cases should receive individualized investigation and care. The here presented recommendations and follow-up from the French allergy community and the Montpellier WHO Collaborating Center in order to support the vaccination program and intends to support to healthcare professionals in their daily basis.
针对新冠病毒（及其新出现的变种）的疫苗是控制当前疫情形势的一项至关重要的全球干预措施。接种严重急性呼吸综合征冠状病毒2（SARS-CoV2）RNA疫苗后曾有过敏反应的报告。过敏反应被定义为一种严重的、危及生命的全身性或系统性超敏反应。在疫苗安全监测项目中，这种风险估计为百万分之一。新冠疫苗接种正在不同国家广泛开展，监测项目对于监测严重不良反应（如过敏反应）至关重要。疫苗引起的过敏反应极为罕见，特定病例应接受个体化调查和护理。本文提出了法国过敏学界和蒙彼利埃世界卫生组织合作中心的建议及随访措施，以支持疫苗接种计划，并旨在为医护人员的日常工作提供支持。
